Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for ₹9.12 crore
Alivus Life Sciences will acquire a 76% stake in IQGEN-X Pharma for approximately ₹9.12 crore. IQGEN-X Pharma, with FY26 turnover of ₹348 Lacs, develops oral solids, sterile injectables, and ophthalmic solutions. The acquisition aims to expand Alivus's API and CDMO offerings. Completion is expected by December 6, 2026.
The acquisition is of a private entity with a relatively small turnover, and the consideration is moderate. While strategic, it might not have an immediate large-scale impact on the parent company's financials.
The company is making a strategic acquisition to expand its business offerings, which is generally viewed positively.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its board of directors has approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. The aggregate consideration for this acquisition is approximately ₹9.12 crore, subject to adjustments as per the Share Purchase Agreement.
IQGEN-X Pharma Private Limited, incorporated in October 2016, is engaged in the formulation development of Oral Solids, Sterile Injectables, and Ophthalmic solutions for regulated and semi-regulated markets. For the financial year ended March 31, 2026, IQGEN-X Pharma reported a turnover of ₹348 Lacs. The company's authorized share capital is ₹2,00,00,000, divided into 20,00,000 equity shares of ₹10 each.
The acquisition is expected to provide Alivus Life Sciences with a wider spectrum to offer end-to-end solutions in both API and CDMO spaces. This transaction does not fall within related party transactions, and no promoter has any interest in the acquired entity. No government or regulatory approvals are required for this acquisition. The indicative time period for the completion of the acquisition is December 6, 2026, or as may be agreed upon, subject to the fulfillment of conditions precedent in the SPA. In case conditions are not met, a Business Transfer Agreement will be executed to acquire the entire business, including employees and assets.
The acquisition involves the purchase of 8,60,589 equity shares of ₹10 each, representing 76% of the paid-up equity share capital of IQGEN-X Pharma Private Limited. The consideration is cash-based.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.